Share This Article:

Pap Test Screening among Vertically HIV-Infected Young Women

Full-Text HTML Download Download as PDF (Size:162KB) PP. 157-161
DOI: 10.4236/aid.2013.33023    3,292 Downloads   5,522 Views  

ABSTRACT

Background: The risk of Human Papillomavirus (HPV) infection and cervical cancer has increased in Human Immunodeficiency Virus (HIV) infected women. Several other Genital Infections (GI), have been shown to act as risk factors for the acquisition of HPV infection and for the development of cervical cancer. Methods: In this observational study, we evaluated the prevalence of HPV infection, GI and cervical abnormalities among vertically HIV-infected young women in the early years of sexual activity. HPV viral strains have been classified as high risk and low risk to develop precancerous and cancerous lesions according to the WHO classification. Results: Eighteen vertically HIV-infected young women and eleven healthy age matched controls were studied. HIV-infected young women showed a higher incidence of high risk HPV genotype infection compared to healthy control. HIV-infected women affected by HPV presented lower levels of CD4+ percentages. GI and Pap test did not show any relation with HPV infection and effects were similar in both groups. Conclusion: HIV infection and low CD4+ percentages seem to play a key role as risk factors for HPV-infection among HIV-infected young women. Therefore, future efforts will be needed to improve the adherence of HIV-infected young women in HPV pap test screening considering the lower ability of these patients to clear the HPV infection.

Cite this paper

H. Tchidjou, N. Cotugno, G. Pontrelli, E. Manno, L. Coltella, D. Rita, S. Baldassari, V. Colizzi, P. Rossi, M. Lucchetti and S. Bernardi, "Pap Test Screening among Vertically HIV-Infected Young Women," Advances in Infectious Diseases, Vol. 3 No. 3, 2013, pp. 157-161. doi: 10.4236/aid.2013.33023.

References

[1] J. Palefsky, “Human Papillomavirus Infection in HIV-Infected Persons,” Topics in HIV Medicine, Vol. 15, No. 4, 2007, pp. 130-133.
[2] J. Kravchenko, I. Akushevich, S.L. Sudenga, C. M. Wilson, E. B. Levitan and S. Shrestha, “Transitional Probability-Based Model for HPV Clearance in HIV-1-Positive Adolescent Females,” PLoS ONE, Vol. 7, No. 1, 2012, p. e30736. doi:10.1371/journal.pone.0030736
[3] T.V. Ellerbrock, M.A. Chiasson, T.J. Bush, X.W. Sun, D. Sawo, K. Brudney and T. C. Wright, “Incidence of Cervical Squamous Intraepithelial Lesions in HIV-Infected Women,” Journal of the American Medical Association, Vol. 283, No. 8, 2000, pp. 1031-1037. doi:10.1001/jama.283.8.1031
[4] R. Setse, G. K. Siberry, W. J. Moss, P. Gravitt, T. Wheeling, B. Bohannon, K. Dominguez and Legacy Consortium, “Cervical Pap Screening Cytological Abnormalities among HIV-Infected Adolescents in the LEGACY Cohort,” Journal of Pediatric and Adolescent Gynecology, Vol. 25, No 1, 2012, pp. 27-34. doi:10.1016/j.jpag.2011.09.002
[5] D. C. Boyle, S. E. Barton, S. Uthayakumar, P. E. Hay, J. W. Pollock, P. J. Steer and J. R. Smith, “Is Bacterial Vaginosis Associated with Cervical Intraepithelial Neoplasia?” International Journal of Gynecological Cancer, Vol. 13, No. 2, 2003, pp. 159-163.
[6] C. Mao, J. P. Hughes, N. Kiviat, J. Kuypers, S. K. Lee, D. E. Adam and L. A. Koutsky, “Clinical Findings among Young Women with Genital Human Papillomavirus Infection,” American Journal of Obstetrics & Gynecology, Vol. 188, No. 3, 2003, pp. 677-684. doi:10.1067/mob.2003.164
[7] D. Saslow, P. E. Castle, J. T. Cox, D. D. Davey, M. H. Einstein, D. G. Ferris, S. J. Goldie, D. M. Harper, W. Kinney, A. B. Moscicki, K. L. Noller, C. M. Wheeler, T. Ades, K. S. Andrews, M. K. Doroshenk, K. G. Kahn, C. Schmidt, O. Shafey, R. A. Smith, E. E. Partridge, F. Garcia and Gynecologic Cancer Advisory Group, “American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors,” CA: A Cancer Journal for Clinicians, Vol. 57, No. 1, 2007, pp. 7-28. doi:10.3322/canjclin.57.1.7
[8] Centers for Disease Control and Prevention, K. A. Workowski and S. M. Berman, “Sexually Transmitted Diseases Treatment Guidelines,” MMWR-Recommendations and Report, Vol. 55, No. RR-11, 2006, pp. 1-94.
[9] E. A. Stier and A. S. Baranoski, “Human Papillomavirus Related Diseases in HIV-Infected Individuals,” Current Opinion in Oncology, Vol. 20, No. 5, 2008, pp. 541-546. doi:10.1097/CCO.0b013e3283094ed8
[10] S. B. Brogly, D. H. Watts, N. Ylitalo, E. L. Franco, G. R. Seage 3rd, J. Oleske, M. Eagle and R. Van Dyke, “Reproductive Health of Adolescent Girls Perinatally Infected with HIV,” American Journal of Public Health, Vol. 97, No. 6, 2007, pp. 1047-1052. doi:10.2105/AJPH.2005.071910
[11] R. P. Nugent, M. A. Krohn and S. L. Hillier, “Reliability of Diagnosing Bacterial Vaginosis Is Improved by a Standardized Method of Gram Stain Interpretation,” Journal of Clinical Microbiology, Vol. 29, No. 2, 1991, pp. 297-301.
[12] A. B. Moscicki, Y. Ma, C. Holland and S. H. Vermund, “Cervical Ectopy in Adolescent Girls with and without Human Immunodeficiency Virus Infection,” The Journal of Infectious Diseases, Vol. 183, No. 6, 2001, pp. 865-870. doi:10.1086/319261
[13] D. Solomon, D. Davey, R. Kurman, A. Moriarty, D. O'Connor, M. Prey, S. Raab, M. Sherman, D. Wilbur, T. Wright Jr., N. Young and Forum Group Members, “Bethesda 2001 Workshop: Terminology for Reporting Results of Cervical Cytology,” Journal of the American Medical Association, Vol. 287, No. 16, 2002, pp. 2114-2119. doi:10.1001/jama.287.16.2114
[14] N. Munoz, F. X. Bosch, S. de Sanjosé, R. Herrero, X. Castellsagué, K. V. Shah, P. J. Snijders, C. J. Meijer and International Agency for Research on Cancer Multicenter Cervical Cancer Study Group, “Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer,” The New England Journal of Medicine, Vol. 348, No. 6, 2003, pp. 518-527. doi:10.1056/NEJMoa021641
[15] D. J. Jamieson, A. Duerr, R. Burk, R. S. Klein, P. Paramsothy, P. Schuman, S. Cu-Uvin, K. Shah and HIV Epidemiology Research Study (HERS) Group, “Characterization of Genital Human Papillomavirus Infection in Women Who Have or Who Are at Risk for Having HIV Infection,” American Journal of Obstetrics & Gynecology, Vol. 186, No. 1, 2002, pp. 21-27. doi:10.1067/mob.2002.119776
[16] L. A. Denny, S. Franceschi, S. de Sanjosé, I. Heard, A. B. Moscicki and J. Palefsky, “Human Papillomavirus, Human Immunodeficiency Virus and Immunosuppression,” Vaccine, Vol. 30, No. S5, 2012, pp. 168-174.
[17] H. De Vuyst, F. Lillo, N. Broutet and J. S. Smith, “HIV, Human Papillomavirus, and Cervical Neoplasia and Cancer in the Era of Highly Active Antiretroviral Therapy,” European Journal of Cancer Prevention, Vol. 17, No. 6, 2008, pp. 545-554. doi:10.1097/CEJ.0b013e3282f75ea1
[18] L. S. Massad, K. A. Riester, K. M. Anastos, R. G. Fruchter, J. M. Palefsky, R. D. Burk, D. Burns, R. M. Greenblatt, L. I. Muderspach and P. Miotti, for Women’s Interagency HIV Study Group “Prevalence and Predictors of Squamous Cell Abnormalities in Papanicolaou Smears from Women Infected with HIV-1,” Acquired Immune Deficiency Syndrome, Vol. 21, No. 1, 1999, pp. 33-41. doi:10.1097/00126334-199905010-00005
[19] L. Ahdieh, R. S. Klein, R. Burk, S. Cu-Uvin, P. Schuman, A. Duerr, M. Safaeian, J. Astemborski, R. Daniel and K. Shah, “Prevalence, Incidence, and Type-Specific Persistence of Human Papillomavirus in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Women,” The Journal of Infectious Diseases, Vol. 184, No. 6, 2001, pp. 682-690. doi:10.1086/323081
[20] A. B. Moscicki, J. H. Ellenberg, S. Farhat and J. Xu, “Persistence of Human Papillomavirus Infection in HIVInfected and -Uninfected Adolescent Girls: Risk Factors and Differences, by Phylogenetic Type,” The Journal of Infectious Diseases, Vol. 190, No. 1, 2004, pp. 37-45. doi:10.1086/421467
[21] S. Cauci, S. Guaschino, S. Driussi, D. De Santo, P. Lanzafame and F. Quadrifoglio, “Correlation of Local Interleukin-8 with Immunoglobulin A against Gardnerella vaginalis Hemolysin and with Prolidase and Sialidase Levels in Women with Bacterial Vaginosis,” The Journal of Infectious Diseases, Vol. 185. No. 11, 2002, pp. 1614-1620. doi:10.1086/340417
[22] P. E. Castle, S. L. Hillier, L. K. Rabe, A. Hildesheim, R. Herrero, M. C. Bratti, M. E. Sherman, R. D. Burk, A. C. Rodriguez, M. Alfaro, M. L. Hutchinson, J. Morales and M. Schiffman, “An Association of Cervical Inflammation with High-Grade Cervical Neoplasia in Women Infected with Oncogenic Human Papillomavirus (HPV),” Cancer Epidemiology, Biomarkers & Prevention, Vol. 10, No. 10, 2001, pp. 1021-1027.
[23] A. B. Moscicki, N. Hills, S. Shiboski, K. Powell, N. Jay, E. Hanson, S. Miller, L. Clayton, S. Farhat, J. Broering, T. Darragh and J. Palefsky, “Risks for Incident Human Papillomavirus Infection and Low-Grade Squamous Intraepithelial Lesion Development in Young Females,” Journal of the American Medical Association, Vol. 285, No. 23, 2001, pp. 2995-3002. doi:10.1001/jama.285.23.2995

  
comments powered by Disqus

Copyright © 2017 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.